Entrada Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Entrada Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.4 times its market value (net cash). Higher than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-3.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 58% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-31.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 64% of Healthcare companies in United States.
Cash Cushion Ratio
1.4× cashCash, after subtracting all debt, is 1.4 times its market value (net cash).
Higher than 92% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Entrada Therapeutics, Inc. made a loss over the last year. Entrada Therapeutics, Inc. owes $0.22 for every $1 it owns. Entrada Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEntrada Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.74The share price is 0.74 times Entrada Therapeutics, Inc.'s book value per share, lower than 85% of Healthcare companies in United States.
Market cap
$172 MThe total market value of all of Entrada Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$233 MWhat Entrada Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.99Net worth divided by the number of shares. The share price of $4.41 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
-54.1%Entrada Therapeutics, Inc. lost 54.1% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
Owes vs Owns
0.22×Entrada Therapeutics, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Dividend yield
NoneEntrada Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-88%Revenue fell 88% in the year to Dec 2025.
Profit growth
LossEntrada Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-565.5%Entrada Therapeutics, Inc. lost $565 for every $100 of revenue.
Cash vs debt
Net cashEntrada Therapeutics, Inc. held $245 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Entrada Therapeutics, Inc.: $172 M ÷ $233 M (30 Jun 2026) = 0.7.
What is Entrada Therapeutics, Inc.'s return on equity?
Entrada Therapeutics, Inc. lost 54.1% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
How much does Entrada Therapeutics, Inc. owe compared with what it owns?
Entrada Therapeutics, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Does Entrada Therapeutics, Inc. pay a dividend?
No. Entrada Therapeutics, Inc. does not currently pay a dividend.
Is Entrada Therapeutics, Inc.'s revenue growing?
Revenue fell 88% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.